Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01318005 · ClinicalTrials.gov registry record · NA

Oral Contraceptive (OC) Estrogen Dose and Breast Proliferation

A NA study, sponsored by University of Southern California.

Completed
Registry status
NA
Development phase
82
Enrollment target

NCT01318005 is a NA study that has completed, run by University of Southern California. The registered enrollment target is 82 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01318005, a NA study, has completed, sponsored by University of Southern California.

COMPLETED
Registry status
NA
Development phase
82 participants
Enrollment target

Study Summary

The purpose of this research study is to gain a better understanding of the changes that may occur in the breast when a woman uses an oral contraceptive (birth control pill). Some research indicates that women who use birth control pills with lower amounts of estrogen (a hormone in the birth control pill) may have lower breast cell growth than women who use birth control pills with a higher amount of estrogen; this research will examine that in detail.

Interventions

  • DRUG Oral Contraceptive: Ortho-Novum® 1/35
  • DRUG Oral Contraceptive: Ovcon® 35
  • DRUG Oral Contraceptive: Microgestin Fe® 1/20

Trial Details

FieldValue
Enrollment Target 82 participants
Start Date 2011-02-14
Est. Completion 2015-06-30
Phase NA

Sponsor

University of Southern California

617 total trials

What the Registry Record Tells You About NCT01318005

The ClinicalTrials.gov registry entry for NCT01318005 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Oral Contraceptive: Ortho-Novum® 1/35 is the first listed.

NCT01318005 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01318005 about?

NCT01318005 is a clinical study titled "Oral Contraceptive (OC) Estrogen Dose and Breast Proliferation". The purpose of this research study is to gain a better understanding of the changes that may occur in the breast when a woman uses an oral contraceptive (birth control pill). Some research indicates that women who use birth control pills with lower amounts of estrogen (a hormone in the birth control...

What is the current status of trial NCT01318005?

This trial is currently completed. It is a NA study. The enrollment target is 82 participants. The study started on 2011-02-14. Estimated completion is 2015-06-30.

What interventions are being tested in trial NCT01318005?

The interventions under investigation include: Oral Contraceptive: Ortho-Novum® 1/35 (DRUG), Oral Contraceptive: Ovcon® 35 (DRUG), Oral Contraceptive: Microgestin Fe® 1/20 (DRUG).

Who is sponsoring clinical trial NCT01318005?

This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.